本科毕业于中山医科大学，2005年获得北京大学医学部肿瘤学博士学位，胸部肿瘤内一科 主任医师，科室副主任，内科教研室常务副主任。CSCO青年专家委员会肺癌专业组委员、CSCO会员、ASCO会员。，2010年赴美国马里兰大学接受博士后培训两年，开展新型抗体治疗的临床前期动物模型研究以及肿瘤分子生物学和肺癌个体化治疗的学习。目前主要从事肺癌多学科综合治疗，擅长肺癌、胸腺癌、胸膜间皮瘤等胸部肿瘤的早期诊断、以内科化疗为主的综合规范化治疗、分子靶向治疗及生物治疗，对生物标志物指导下的肺癌个体化治疗有深入研究，熟练掌握肺癌的最新国际诊疗规范，参加20余项国际、国内多中心临床研究，及时掌握国际肺癌诊治前沿新动向。
专业特长
从事肿瘤临床工作近14年，在胸部肿瘤尤其是肺癌的多学科综合治疗上有丰富经验及深厚的学术造诣，擅长肺癌早期诊断以及规范化、个体化多学科综合治疗及气管镜、TBNA、内科胸腔镜等局部治疗及操作。
研究成果
2008年获得北京肿瘤医院北京市肿瘤防治研究所所内基金，先后获得教育部科技成果二等奖、华夏科技成果二等奖及北京市科技进步三等奖、中华医学奖三等奖等奖励。
主要论著
1) MeinaWua, Jun Zhao(equal contribution）, SonyaWei Song, Minglei Zhuo, XinWang, Hua Bai, ShuhangWanga, Lu Yang, Tongtong An, Yan Zhang, Jianchun Duan, YuyanWang, Qingzhi Guo,Xuyi Liu, Ninghong Liu, JieWang. Plasma EGFR mutations are not associated with response to first-line chemotherapy but with prognosis in the Chinese patients with advanced non-small cell lung cancer. lung cancer 2010, 67(3):343-347
2) Jun Zhao, Zhi-jie Wang, Jian-chun Duan, Qing-zhi Guo, Hua Bai, Lu Yang, Tong-tong An, Xin Wang, Yu-yan Wang and Mei-na Wu, et al. A Phase II Clinical Trial of Celecoxib Combined with Platinum-Based Regimen as First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients with Cyclooxygenase-2 Positive Expression. Chinese journal of cancer research, 2009，21(1)： 1-12.
3) Xin Wang, Jun Zhao, Lu Yang, Li Mao,Tongtong An, Hua Bai,Shuhang Wang ,Xuyi Liu,Guo shuang Feng, Jie Wang. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 2010,27(2):484-490
4) Hua Bai, Zhijie Wang, Keneng Chen, Jun Zhao, Shuhang Wang, Qinghua Zhou, Minglei Zhuo, Tongtong An, Jianchun Duan, Lu Yang, Meina Wu, Zhen Liang, Yuyan Wang1, Xiaozheng Kang, Jie Wang. Influence of Chemotherapy on EGFR Mutation Status for Patients with Non-small Cell Lung Cancer. J Clin Oncol，2012
5) Shuhang Wang, Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Minglei Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, and Meina Wu.Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced NSCLC. Clin Cancer Res 2010, 15,16(4):1324-1330
6) 赵军，刘叙仪，张青云，蒋薇。晚期非小细胞肺癌外周血VEGF和BFGF及MMP-9水平与预后的关系。中华肿瘤杂志 2005; 27: 676-679
7) 白桦,赵军,王书航,安彤同,王鑫,吴梅娜,段建春,杨鹭,郭庆志,刘宁红,王洁.变性高效液相色谱法检测非小细胞肺癌人群外周血和配对肿瘤组织EGFR突变。中华结核和呼吸杂志，2008，31：891-896
8) Wu M, Wang Y, An T, Zhao J, Yang L, Duan J, Wang Z, Zhuo M, Bai H, Liu X, Wang J. Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer. Zhong guo Fei Ai Za Zhi. 2011 Mar;14(3):245-50
9) Wang Z, Yang L, An T, Zhao J, Bai H, Duan J, Wu M, Zhou M, Wang Y, Wang J. The Association between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A meta-analysis. Zhong guo Fei Ai Za Zhi. 2009 Dec 20;12(12):1247-54.
10) Yang L, Lu QY, Wu MN, An TT, Zhao J, Guo QZ, Duan JC, Wang J. A retrospective analysis: comparison of the clinical characteristics and prognosis in elderly and young patients with locally advanced or metastatic non-small cell lung cancer. Zhonghua Jie He He Hu Xi Za Zhi. 2009 Nov;32(11):830-4.
11) Wang J, Lu C, Liu XY, Zhang HB, Zhao J, Yang L, Guo QZ, An TT, Wu MN. Distinguishing second primary tumors from lung metastasis in patients with postoperative non-small cell lung cancer by microsatellite analysis. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):103-7